Bosch Chairman Warns of Revenue Decline and Potential Job Cuts 
Sumitomo Corp Reports 11% Drop in Net Profit Amid Weak Coal Prices 
Xiaomi SU7 Ultra Pre-Sale Begins in China for $114K with 1,500 HP, Hits 100 km/h in 2 Seconds 
Samsung Electronics Refocuses on High-End Chips Amid Profit Dip and AI Demand 
BYD Hints at Seagull EV Arrival in Australia, Could Become Nation's Cheapest Electric Car 
BOJ Maintains Low Interest Rates Amid Economic Scrutiny 
Samsung’s AI-Led Profit Recovery Stumbles as Rivals Seize the Lead in Booming Chip Market 
XRP's Decentralized ID Revolutionizes Digital Security: Self-Sovereign IDs Go Live on XRPL 
Shiba Inu's Shytoshi Unveils Unprecedented 33,774,726% SHIB Surge, Overshadowing Bitcoin and Dogecoin 
Toyota and Suzuki’s First All-Electric SUV Hits Global Markets in 2025: Here’s What’s Coming 
PepsiCo Uses Retailer Purchase Data to Drive Accurate Forecasting, Tackle Slumping Snack Sales 
Solana ETF Filed with SEC as Canary Capital Heats Up the Crypto Race with New Proposal 
Utilizing Blockchain Technology for Transparent and Decentralized Gold Trading 
Bitcoin Miners Turn to AI and Strategic Mergers as Halving Pressures Profitability: CoinShares Report 
Inside Today’s Crypto Boom: Bitcoin’s $70K Triumph and Trump’s Rising Poll Advantage Fuel Bull Run 
Visa Tops Profit Expectations as Consumer Spending Defies Economic Concerns and Drives Growth 
OpenAI Taps TSMC and AMD for 2026 Launch of Custom AI Chips 
PRINCETON, N.J., Feb. 02, 2017 -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company, announced today that its Chief Executive Officer, Al Altomari will present at the 2017 BIO CEO & Investor Conference on Monday, February 13, 2017 at 11:00 am ET at the Waldorf Astoria in New York.
To access the live and archived webcasts of the presentation, visit the Investor Relations section of Agile Therapeutics website at www.agiletherapeutics.com. The webcast will be archived on Agile Therapeutics website for 60 days following the event.
About Agile Therapeutics
Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. For more information, please visit the company website at www.agiletherapeutics.com.
Contact: Mary Coleman 609-683-1880
